Ana Sayfa
Piyasalar
Grafikler ve Fikirler
Algo
Haberler
Store
Aracı Kurumlar
İndir
Ekonomik Takvim
Alım-Satım Sinyalleri
Web Terminali
Heatmap
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
TCRX
#4285
TScan Therapeutics, Inc. Common Stock
1.0
6
USD
+3.92%
Sektör:
Sağlık Hizmetleri
Baz:
USD
Kar Para Birimi:
USD
Günlük Aralık
Yıllık Aralık
Günlük Değişim
+3.92%
Aylık Değişim
-2.75%
6 aylık değişim
-50.00%
Yıllık Değişim
-13.11%
Önceki Kapanış
1.0
2
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Hacim
8
Piyasalar
ABD Borsası
Sağlık Hizmetleri
TCRX
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
18.76 M
19.08 M
43.61 M
52.31 M
52.63 M
—
Valuation ratios
Enterprise value
-53.51 M
-58.11 M
145.68 M
12.42 M
-67.25 M
-219.59 M
Price to earnings ratio
—
-0.62
-4.2
-2.67
-1
-5.26
Price to sales ratio
—
3.25
21.72
120.9
12.57
143.87
Price to cash flow ratio
—
-0.62
-6.1
-3.07
-0.96
-5.5
Price to book ratio
—
0.41
2.48
1.41
1.05
1.72
Enterprise value to EBITDA ratio
1.18
0.02
-2.23
-0.59
0.04
-0.11
Profitability ratios
Return on assets %
-0.26
-0.33
-0.33
-0.34
-0.57
-0.46
Return on equity %
-0.3
-0.67
-0.59
-0.53
-1.05
-0.81
Return on invested capital %
-350.58
-290.57
-270.29
-374.26
-584.75
—
Gross margin %
100
107.12
122.03
100
100
400
Operating margin %
-479.65
-527.39
-541.82
-4 787.68
-1 315.38
-5 331.34
EBITDA margin %
-446.83
-493.86
-532.77
-4 641.8
-1 287.62
-5 218.7
Net margin %
-479.49
-524.11
-517.24
-4 527.66
-1 256.81
-5 090.48
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.76
7.17
6.51
8.14
8.41
30.46
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.05
0.07
0.07
0.01
0.03
0.04
Solvency ratios
Debt to assets ratio
—
0.15
0.11
0.09
0.14
0.47
Debt to equity ratio
—
0.29
0.2
0.13
0.26
0.83
Long term debt to total assets ratio
—
0.15
0.1
0.09
0.14
0.47
Long term debt to total equity ratio
—
0.29
0.18
0.13
0.26
0.83
Per share metrics
Operating cash flow per share
—
-2.77
-0.94
-0.99
-1.04
-1.04
EBIT per share
—
-2.81
-1.48
-1.2
-1.05
-1.05
EBITDA per share
—
-2.59
-1.4
-1.17
-1.02
-1.02
Total debt per share
—
1.22
0.46
0.29
0.25
1
Cash per share
—
4.99
2.93
2.59
1.17
6.22
Net current asset value per share
—
5.16
2.96
2.61
1.21
6.33
Tangible book value per share
—
4.13
2.3
2.15
0.95
5.04
Working capital per share
—
4.44
2.51
2.29
1.07
5.49
Book value per share
—
4.13
2.3
2.15
0.95
5.04
Haberler
H.C. Wainwright, Tscan hissesi için Al tavsiyesini yineledi
TScan Therapeutics finans başkan yardımcısının istifasını açıkladı
Buy 2 ‘Strong Buy’ Biotech Stocks With 400%+ Upside, According to Wall Street - TipRanks.com
Tscan Therapeutics kazancı $0,09 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek
Tscan Therapeutics earnings beat by $0.09, revenue topped estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan deneme kohort kaydını tamamladı, FDA onayı aldı
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates